Medpace Reports Mixed Q4 Earnings, Issues FY22 Guidance Ahead Of Estimates

Medpace Holdings Inc's MEDP Q4 revenue increased 18.8% Y/Y to $308.6 million, missing the consensus of $309.04 million. On a constant currency organic basis, revenue increased 19.2%.

  • As of December 31, 2021, Backlog grew 29.5% to $1.99 billion. Net new business awards were $458.7 million, representing a net book-to-bill ratio of 1.49x.
  • EBITDA for Q4 FY21 increased 2.0% to $61.4 million, or 19.9% of revenue, compared to $60.2 million, or 23.2% of revenue, for the comparable prior-year period.
  • The Company posted EPS of $1.32, down from $1.35 posted a year ago and beating the consensus of $1.25.
  • Additionally, as of February 10, the Company's Board of Directors approved an increase of $300 million to the Company's stock repurchase program.
  • Financial Guidance: Medpace forecasts FY22 revenue of $1.4 billion - $1.46 billion, representing Y//Y growth of 22.6% - 27.8%, compared to the consensus of $1.44 billion.
  • EBITDA is expected to be $262 million - $278 million. 
  • The Company expects EPS of $5.35 - $5.67, versus the consensus of $5.49.
  • Price Action: MEDP shares closed at $174.23 on Monday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: EarningsNewsGuidanceHealth CareBuybacksGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!